Risk factors for severe respiratory syncytial virus infection in elderly persons - PubMed

Affiliations

• PMID: 14722887
• DOI: 10.1086/380907

Risk factors for severe respiratory syncytial virus infection in elderly persons

Edward E Walsh et al. J Infect Dis. 2004.

Abstract

Risk factors for severe respiratory syncytial virus (RSV) infection were determined in 3 cohorts of adults during 2 consecutive winters (1999-2000 and 2000-2001) in Rochester, New York. Community-dwelling healthy persons > or =65 years old and persons >21 years old who had underlying symptomatic cardiopulmonary conditions were prospectively evaluated for RSV infection. Evidence of infection was also sought in persons who were > or =65 years old or had underlying cardiopulmonary disease and who were hospitalized with acute respiratory symptoms. Sixty-nine RSV infections were identified by culture, reverse-transcription polymerase chain reaction, or serologic testing in the prospective groups, and 61 were identified in the hospitalized group. The presence of underlying chronic pulmonary disease (odds ratio [OR], 3.97), functional disability (OR, 1.67/integer increase in Instruments of Activities of Daily Living score), and low serum neutralizing antibody titer (OR, 5.89) were each independently associated with increased risk of severe disease, defined as "hospitalization with RSV infection." These data suggest that the induction of neutralizing serum antibody with an RSV vaccine may potentially reduce disease severity in adult populations.

Similar articles

• Respiratory syncytial virus infection in elderly and high-risk adults.

  Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Falsey AR, et al. N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951. N Engl J Med. 2005. PMID: 15858184

• The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.

  Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, O'Brien KL. Eick A, et al. Pediatr Infect Dis J. 2008 Mar;27(3):207-12. doi: 10.1097/INF.0b013e31815ac585. Pediatr Infect Dis J. 2008. PMID: 18277934

• Age related differences in humoral immune response to respiratory syncytial virus infection in adults.

  Walsh EE, Falsey AR. Walsh EE, et al. J Med Virol. 2004 Jun;73(2):295-9. doi: 10.1002/jmv.20090. J Med Virol. 2004. PMID: 15122807

• Respiratory syncytial virus infection in adults.

  Falsey AR. Falsey AR. Semin Respir Crit Care Med. 2007 Apr;28(2):171-81. doi: 10.1055/s-2007-976489. Semin Respir Crit Care Med. 2007. PMID: 17458771 Review.

• Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.

  Johnson TR, Graham BS. Johnson TR, et al. Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.

Cited by

• Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity.

  Brown PM, Schneeberger DL, Piedimonte G. Brown PM, et al. Paediatr Respir Rev. 2015 Sep;16(4):232-40. doi: 10.1016/j.prrv.2015.05.005. Epub 2015 May 23. Paediatr Respir Rev. 2015. PMID: 26074450 Free PMC article. Review.

• Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

  Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE, Falsey AR. Walsh EE, et al. J Infect Dis. 2013 May 1;207(9):1424-32. doi: 10.1093/infdis/jit038. Epub 2013 Feb 4. J Infect Dis. 2013. PMID: 23382572 Free PMC article.

• Rate of Hospitalizations and Mortality of Respiratory Syncytial Virus Infection Compared to Influenza in Older People: A Systematic Review and Meta-Analysis.

  Maggi S, Veronese N, Burgio M, Cammarata G, Ciuppa ME, Ciriminna S, Di Gennaro F, Smith L, Trott M, Dominguez LJ, Giammanco GM, De Grazia S, Costantino C, Vitale F, Barbagallo M. Maggi S, et al. Vaccines (Basel). 2022 Dec 7;10(12):2092. doi: 10.3390/vaccines10122092. Vaccines (Basel). 2022. PMID: 36560501 Free PMC article. Review.

• Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease.

  Kim YJ, Guthrie KA, Waghmare A, Walsh EE, Falsey AR, Kuypers J, Cent A, Englund JA, Boeckh M. Kim YJ, et al. J Infect Dis. 2014 Apr 15;209(8):1195-204. doi: 10.1093/infdis/jit832. Epub 2013 Dec 23. J Infect Dis. 2014. PMID: 24368837 Free PMC article.

• Nanoparticle vaccines against respiratory syncytial virus.

  Stephens LM, Varga SM. Stephens LM, et al. Future Virol. 2020 Nov;15(11):763-778. doi: 10.2217/fvl-2020-0174. Epub 2020 Nov 30. Future Virol. 2020. PMID: 33343684 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information